Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026…
February 28, 2026 09:45 ET | Source: Cogent Biosciences, Inc. Bezuclastinib mean TSS reduction deepens to –32.0 points at 48…
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA…